, Tracking Stock Market Picks
Enter Symbol:
Rating: IPXL
Buy $37

Impax Laboratories, Inc. (NASDAQ: IPXL) upgraded to Buy with price target $37 by Needham

Friday,  Oct 10, 2014  8:25 AM ET by Betsy O'Brien Harrison

Needham upgraded Impax Laboratories, Inc. (NASDAQ: IPXL) to Buy with price
target $37. Previously Needham upgraded to Impax Laboratories, Inc. (NASDAQ: IPXL) to Hold on 03/23/2010, when the stock price was $17.60.

Impax Laboratories, Inc. is a technology-based, specialty pharmaceutical company. The Company is focused on the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development and formulation expertise. In the generic pharmaceuticals market, the Company focuses its efforts on controlled-release generic versions of selected brand-name pharmaceuticals covering a range of therapeutic areas. In the brand-name pharmaceuticals market, Impax is developing products for the treatment of central nervous system (CNS), disorders. Its brand-name product portfolio consists of development-stage projects to which it is applying its formulation and development expertise to develop differentiated, modified, or controlled-release versions of marketed drug substances. The Company operates in two segments: Global Pharmaceuticals Division (Global Division) and the Impax Pharmaceutical Division (Impax Division).

Needham & Company, LLC focuses on emerging growth companies in technology, biotechnology and life sciences. The firm's research goal is to service the needs of growth-oriented institutional clients. Needham & Company has established itself as a premier specialty investment bank providing timely and valuable analysis on companies that are under-covered by the majority of Wall Street firms.

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy